carglumic acid
|
|
|
- ゆりな おおばま
- 9 years ago
- Views:
Transcription
1
2 carglumic acid
3
4 carglumic acid (rinn)
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23 JueI VC, Massey lr,l. Myasthenia gravis. Orphanet J Rare Dis Nov 6i2:44. Leonardi M, Raggi A, Antozzi C, Confalonieri P, Maggi L, et al. The relationship between health, disability and quality of life in Myasthenia Gravis: results from an Italian study. J Neurol Jani257: doi /s Epub 2009 Aug 8. Matsuda M, Dohi-lijima N, Nakamura A, et al. Increase in incidence of elderly onset patients with myasthenia gravis in Nagano Prefecture, Japan. Intern Medicine Jun, 44 (a):stz-1. Murai H, Yamashita N, Watanabe M, Nomura Y, et al. Characteristics of nyasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci. 20tl Jun 15; 305(l-2) i doi: /j. jns.20lt epub2ol1 Nlar 26. Okinaka S, Reese HH, Katsuki S, et al. The prevalence of multiple sclerosis and other neurological diseases in Japan. 1966,47 (Suppl l9): Romi F, Gilhus NE, AarIi Jn. Myasthenia gravis: clinical, immunological, and therapeutic advances. Acta Neurol Scand Feb; 111(2):134-4I.
24
25
26
27
28
29
30 AUCo-e (ng'tu,/nn-)
31
32
33
34
35
36
37
38
39 I lq!e+ti
40
41 87
42
43
44
45
46
47
48 ):, I -, *rjrjn-,
49
50 6 2tL7 7
51 9.7 a?/1r ) r1qlonl
52
53
54
55
56
57
58
59
60 t24 'oe 1- I
61
62
63
64
65
66
67 Co (nc/ml)
68 s(+)l+ifvu (mllmrn) X (nglml)
69 tttto 7) sc/i,!$fij (300rgl E tfl) *5$offiH*o
70 copies/ml- =too,ooo Sloo,ooo copies/ml-
71
72
73
74
75
76 $mso 54 6mg 75 6mg D--? > = l--/v 36.0mg 2 Omg 27mg Q connoo"orr
77 028 mg'/ml 7Omg 0.28 mg,/ml ntg,/ ml ng,/ml 50mg /:4 7 tv 047 mg,/ml l4{ mg,/ml mg'/ml mg'/ml mg,/ml Q comomtrt
78 177ev >y 4C7Y> 7 -= l-y' 7+tt / t t> )l tv ts-v P e> Q Comornurt
79 C Codrd.tr{.1
80 0 { 3 r? r 3 { 5 6 I 3 9lr1rr, 0 a 12 $ an 31 *+t9i:1+t) &+B i=ir a+gsi_t r+ui I l3e_xlzbrrf,9fofit+utel s4iqrri 6e t 1pj (hr) {64.46,78 4l) t06.61 (94.73, r l9 98) t 4 l.l9 (132 64, I 50 30) (7.97, t0.0t) t4.m ( r3.4q l5 45) t7.21 ( ) l.l + (094, 1.38) 1.53 (1.21,194) 22E u ) 0.62,1.76) t.l6 (1.13, I l9) ,200) z,t I u 99, 2.38) t , r 8l) 2.12 (2.46,3 0t) G csftd.nffit
81 AUCuz+r fue'tr,/rl\ C tn. (!s,,/ rj.\ c2451 (rs./ml \ AUCou +n, (ub'tu/nj,\ Crr fus'/nl]. c2g1 (ro./mr \ ll lr ( ) 2.4r fl.8.3.4) (L t74.29\ l8.39ll /L ',1 1.90! i \ t45.99 (l s6.53\ (L3t.t \ 25.96s 17.17r ( \ fi5.80. I \ 2.41! ( ) ( \ ( ) I 5.88! (L0.2s.24.60\ 3.01{ fl ) Q Cortactrat
82 Q cornootrr
83 Q Cornornu*
84
85 r: i? y 2 zl tv 0.75%
86 vt.y ) 7, )v0.75% 7 tv=-)v
87
88
89
90
91 *77aiE:fiil 5pg azyv>y *7Aaid:fril 20rrg arrury *A7oEHil 60ug 72rU>Y
92 I 5ue
93
94
95
96
97
98 t Elffi tt+tvz ito.lb ' il#tr, r\t tv2 No.2o t Elffi r\l.tvz No.2z o ilffi, tt+.tvz t{0.24
99 t'l ET tv=*tv N.N'-t 7 - =)V,t:, 7 - = V l,/ )7 :. >
100 x7:a- 1., ztrty]/z- /\1.,7- -79*yV=
101
102
103
104
105
106
107 -49,999,,\
108
109
110
111
112
2 (1) (2) SCI 2 SCI 2 24 2 12 2
2004 (1) (2) (2) (3) (1) 1 (2) (3) 2 (1) (2) SCI 2 SCI 2 24 2 12 2 100% / 16 2002 2003 http://lin.lin.go.jp/alic/month/dome/1997/nov/chousa.htm (05 612 1315 1618 1922 2329 3039 4049 5059 60 ) =10 b g 1
Q E Q T a k Q Q Q T Q =
i 415 q q q q Q E Q T a k Q Q Q T Q = 10 30 j 19 25 22 E 23 R 9 i i V 25 60 1 20 1 18 59R1416R30 3018 1211931 30025R 10T1T 425R 11 50 101233 162 633315 22E1011 10T q 26T10T 12 3030 12 12 24 100 1E20 62
求人面接資料PPT
Hair Salon TV etc. 250" 250" 200" 200" 150" 150" 100" 100" 50" 50" 0" 0" Nov)13" Dec)13" Jan)14" Feb)14" Mar)14" Apr)14" May)14" Jun)14" Jul)14" Dec)12" Jan)13" Feb)13" Mar)13" Apr)13"
14 35H-3 35H-3 15 b f f b b b f f f f f f f f f f b b f f f f f b b b b b b b b b f f f f f f f f f f f f f
bff b b b ff ff ff f f ff b b ff ff f b b b b b b b b b f f f f f f f f f f f f f b b ï ñ ó ff ff ò ô ö ù û û Æ õ ú ü! bõ ú b μ b b b f f f f f f f f f f f f b b bõ fl fi f f f f f f f f b b b b@ b b ff
et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology
37 Recommendations for the Management of Moyamoya Disease A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) Research on intractable diseases of the
32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
il E ------------= 5E 1B H 171819 l /\yl-.';t'.-/t rl -,1i* [ F,li*/L .7 F rli- r" )'> F,f.*)v 'u,, tv ,/tvz '/u, )v 7./:/, )v7 /7tvz t'//lv7 oebrft tt ''No,2R.4
zrtt-^fi.-.zl, . i f.,t, -zl, +lv)t* v-,f,.- L,)l;f- L ,)ll'- L,a,v^ i>/,va 4/ tvz /'/ tvz t\/ 1-n Ef, (3) 4 551drtl }E--EE(2] 4-JZG. o luanrr i *0.5i 2oomi I T/iE] l 9/ t4 9/15 :r-r'87>
2.2 緒言エクリズマブ エクリズマブ ソリリス点滴静注 300mg 第 2 部 CTD の概要 2.2 緒言 アレクシオンファーマ合同会社
エクリズマブ ソリリス点滴静注 300mg 第 2 部 CTD の概要 2.2 緒言 アレクシオンファーマ合同会社 目次 2.2 緒言... 3 2.2.1 参考文献... 5 頁 2 / 5 2.2 緒言 重症筋無力症 (MG) は 神経筋接合部 (NMJ) における自己抗体の結合による神経筋伝達異 常が原因で引き起こされる 稀な消耗性の後天性自己免疫性神経障害である こうした自己抗体は 神経伝達物質であるアセチルコリンによる筋への神経刺激伝達のために不可欠であるアセチルコリン受容体
L
-G -VG -G -VG.MPa..MPa.1MPa..MPa 1.5MPa 1.5MPa 1.5MPa 1.5MPa 1 s 5 5 - -V 1.51MPa 1.5MPa s s..mpa.mpa 1.5MPa 1.5MPa - -V 1 s s 5 5 1 JISg/H 1. 1.5. 11 SLLBFFB SLLBFTC CCCCBTC..MPa 1.5MPa SLLBFFB CCCCBTC
) 5 Lawton QOL 4 4 QOL Lawton 4) Philadelphia Geriatric Center Affect Rating ScaleARS ARS QOL 5) HDS R
Vol. 12 No. 2 2002 389 397 Λ1 Λ2 16 10 30 1 2 Lawton Philadelphia Geriatric Center Affect Rating ScaleARS Lawton ARS + ARS 6 2 ARS 2 12:00 15:0017:00 11:30 16:00 1 2 ARS 1 2 ARS QOL QOL QOL 1) QOL QOL
untitled
5 K 5 3 HP http://www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/taikou03.html 2004 1 2 1 http://www.dm-net.co.jp/calendar/2007/06/005835.php 6 85cm 100cm 2 90cm 2 TG 150mg/dl HDLHDL-C 40mg/dl 130mmHg 85mmHg
2.
2. 10 2. 2. 1995/12006/111995/42006/12 2. 10 1995120061119954200612 02505 025 05 025 02505 0303 02505 250100 250 200 100200 5010050 100200 100 100 50100 100200 50100 10 75100100 0250512 02505 1 025051205
596_H1H4.indd
2014 Aug. 8No.596 http://www.saitama-ctv-kyosai.net 1021 1125 1127 10 10 27 11 11 17 11 11 20 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
油圧1.indd
4 2 ff f f f f f f f f f f f f ff ff ff r f ff ff ff ff ff ff R R 6 7 φφ φφ φφ φ φ φφ φφφφφφφφ φφφφ φφφφ φφ! φ f f f f f f f f f f 9 f φ φ φ φ φ φ φ φ φφ φφ φ φ φ φ SD f f f KK MM S SL VD W Y KK MM S SL
NVA-HD1680DT
NVA-HD1680DT v z m qu m L L L L L t t r e w _ _ z z z z z z z zz z z z z z z z z z zz z z z z z z z z z 1 z 3 1.. 1 1 1.. 1 tc 1 J v m 1 v z z z z z z z 1 3 4 7 8 9 9 7 1 5
22 25 34 44 10 12 14 15 11 12 16 18 19 20 21 11 12 22 10 23 24 12 25 11 12 2611 27 11 28 10 12 29 10 30 10 31 32 10 11 12 33 10 11 12 34
22 25 34 44 10 12 14 15 11 12 16 18 19 20 21 11 12 22 10 23 24 12 25 11 12 2611 27 11 28 10 12 29 10 30 10 31 32 10 11 12 33 10 11 12 34 35 10 12 36 10 12 37 10 38 10 11 12 39 10 11 12 40 11 12 41 10 11
Special IssueDiagnoses and therapeutic agents for age-related diseases Reviews Original Case reports β Medicinal drugs affecting on clinical laboratory blood test results and adverse effects of them
C-1 210C f f f f f f f f f f f f f f f f f f f f r f f f f f f f f f f f f f R R
4 5 ff f f f f f f f f f f f f ff ff ff r f ff ff ff ff ff ff R R 7 b b ï φφ φφ φφ φ φ φφ φφφφφφφφ φφφφ φφφφ ù û û Æ φ ñ ó ò ô ö õ φφ! b ü ú ù û ü ß μ f f f f f f f f f f b b b z x c n 9 f φ φ φ φ φ φ
油圧1.indd
ff ff ff ff f f ff ff ff f f f f f f f f f f f f f f ff ff! f f f f f f f ff ff f f ff f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f S 9 M6 M6 M6 M. 6 6 R/ P M. M. M. M. f f f 96 f f f M.
(35H-3).pm
ff f f f f f f f f f f f f f ff ff ff f f ff ff ff f ff ff! f f f f f f f f f f f f f ff ff f f ff f f f f f f f f f f f f f f f f f f f f f S f f f f f f 9 M6 M6 M6 M. M. M. M. M. 6 6 9 R/ R/ P M. M.
Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS
RS Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS1998 7020021BPD 200510CHD 50mg100mg2012 812 RS20138 RS Respiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 28 2935 RS 12 6 RS BPD
36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: , 要旨 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visi
36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: 378 384, 2014 1 2 要旨 1999 2012 10 31 29 26 80 30 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visit time, chronological change はじめに 4 12 23 27 1 Japan
NV-JM525DT
NV-JM55DT z k FOR USE IN JAPAN ONLY RR6P40A45500A L LL qr q w e r z > 50 L L L L L L L L t t t r e w +_ z z z z z z z z z z z z z z z z z z z z z z z z z z z z z z z z z z z z
194621 22 50.06 53.96 90.00 28 87.14 85.00 80.00 75.00 70.00 22 53.96 28 80.75 65.00 60.00 55.00 22 50.06 50.00 Quality of Life !! 281026 281026 -6,500-5,500-4,500-3,500-2,500-1,500-500 500 1,500 2,500-6,401-1,281-3,565-2,154-2,265-2,027-1,869-1,657
volunteer_kobe
1 2 2 3 4 15 80 i 3 8 8 14 18 21 25 35 35 40 44 53 59 59 64 66 72 81 84 86 1 1 88 ii 90 92 94 55 96 101 102 104 106 108 110 112 113 114 115 118 120 122 124 126 130 132 133 134 135 136 138 139 140 141 145
1) University Group Diabetes Program: A study of hypoglycemic agents on vascular complica- in patients with adult-onset tions diabetes. I. Design, methods and baseline results. Diabetes 19 (suppl. 2):
千葉県における温泉地の地域的展開
1) 1999 11 50 1948 23) 2 2519 9 3) 2006 4) 151 47 37 1.2 l 40 3.6 15 240 21 9.2 l 7. 210 1972 5) 1.9 l 5 1 0.2 l 6 1 1972 1.9 0.4 210 40-17- 292006 34 6 l/min.42 6) 2006 1 1 2006 42 60% 5060 4050 3040
がん患者の終末期ケアにおける通所リハビリテーションの役割 介護保険によるがん終末期ケアの可能性
2 3 3 6 7 49 53 13 61 22 27 65 68 34 47 71 73 4 5 7 6 8 9 10 11 12 13 14 15 44 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
